9MW1911
/ Mabwell (Shanghai) Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
December 18, 2023
Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD).
(clinicaltrials.gov)
- P1/2 | N=80 | Recruiting | Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
New P1/2 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases
March 15, 2023
A Clinical Study in Healthy Subjects to Evaluate 9MW1911 Injection
(clinicaltrials.gov)
- P1 | N=28 | Completed | Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. | Recruiting ➔ Completed
Trial completion • Asthma • Atopic Dermatitis • Chronic Obstructive Pulmonary Disease • Dermatitis • Dermatology • Immunology • Pulmonary Disease • Respiratory Diseases
April 29, 2022
A Clinical Study in Healthy Subjects to Evaluate 9MW1911 Injection
(clinicaltrials.gov)
- P1 | N=38 | Recruiting | Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Asthma • Atopic Dermatitis • Chronic Obstructive Pulmonary Disease • Dermatitis • Dermatology • Immunology • Pulmonary Disease • Respiratory Diseases
1 to 3
Of
3
Go to page
1